Introduction

The Canadian Cancer Research Alliance (CCRA) is an alliance of organizations that collectively fund most of the cancer research conducted in Canada – research that will lead to:

  • better ways to prevent cancer
  • diagnose cancer
  • treat cancer and
  • improve patient and survivor outcomes.

Members include federal research funding programs/agencies, provincial research agencies, provincial cancer care agencies, cancer charities, and other voluntary associations. 

We are motivated by the belief that, through effective collaboration, Canadian cancer research funding organizations can maximize their collective impact on cancer control and accelerate discovery for the ultimate benefit of Canadians affected by cancer.

Our Executive Office is supported by the Canadian Partnership Against Cancer, an independent, not-for-profit organization funded by the federal government to accelerate action on cancer control for all Canadians. For more information on the Partnership’s role, click here.

The CCRA is not a registered charity and cannot accept donations. If you wish to donate to a charity that funds cancer research, please check our Members page.

CCRA... 

  • has been publishing reports on the annual investment in cancer research in Canada since 2007 (to access, click here)
  • also publishes research investment reports on childhood and adolescent cancers, cancer risk and prevention, early translation, survivorship, and palliative and end-of-life care (to access, click here)
  • has developed two pan-Canadian cancer research strategies, which identify key priorities for cancer research funding collaboration (to access, click here)
  • has produced specific research frameworks for prevention, survivorship, and palliative and end-of-life care, as well as a report on the state of cancer clinical trials in Canada (to access, click here)
  • CCRA’s publications have been cited in more than 50 scientific papers (for a listing of these papers, click here)
  • has convened three scientific conferences, with the fourth scheduled for November 2017 in Vancouver (for more information, click here)
  • recognizes, on a biennial basis, the accomplishments of key leaders in cancer research (for more information, click here).

New Section on PartnershipAgainstCancer.ca

The Partnership is pleased to announce a brand new section - Topics - on its website PartnershipAgainstCancer.ca. Topics is now home to the most valuable information from Cancerview.ca, which has just been sunsetted. Topics provides evidence-based information for the cancer control community and is user-friendly, optimized for search engines, viewable on all devices, and accessible. Go to Topics and let the Partnership know what you think!

$473M Invested in Cancer Research in 2016

CCRA released its latest reports on the investment in cancer research. In addition to the overview report, there are brief reports on the research investments made in childhood and adolescent cancers, cancer risk and prevention, cancer survivorship, palliative and end-of-life cancer care and translational research. Reports are available in PDF formats and have accompanying slide decks that expand on the report analyses.

To access the annual report, click here. For the special topics reports, click here.

Call for Nominations for 2019 CCRA Awards

In 2011, the CCRA initiated a biennial recognition program consisting of three awards to acknowledge and celebrate the contributions of individuals who have had a remarkable impact on cancer research and the cancer research community. In 2017, the CCRA announced a new award recognizing exceptional leadership in patient involvement in cancer research. These awards are presented during the Canadian Cancer Research Conference.

To submit a nomination, please provide the nominee’s name and a brief paragraph detailing the reasons for nomination to Diana Soifer (This email address is being protected from spambots. You need JavaScript enabled to view it.) by the end of day on May 15, 2019. Nominations are open to all, including past nominees.

Dr. Cindy Bell is CCRA's New Chair

At the December 2018 CCRA Member Meeting, Dr. Cindy Bell, Genome Canada's Executive Vice-President, Corporate Development, transitioned from Chair-elect to CCRA Chair. Dr. Bell was elected from among the organizational representatives and will serve a two-year term.

Members recognized the invaluable contributions of outgoing Chair, Dr. Stephen Robbins, Scientific Director, CIHR Institute of Cancer Research. Dr. Robbins will remain in the Past-Chair capacity until December 2019.

Other News and Events...

New Logo, New Look

The Terry Fox Research Institute introduced a new logo and launched a new website to reflect the innovative nature of its research. Check it out! In addition, the 2019 Federal Budget included an investment of up to $150M over the next five years for the Marathon of Hope Cancer Centres network. The network will be officially launched on April 12, 2019 in St. John's -- the same day and place where Terry began his Marathon of Hope 39 years ago. For more, see https://www.tfri.ca/our-research/marathon-of-hope

BioCanRx Targeted Funding - Cycle II

BioCanRx, Canada’s Immunotherapy Network, is pleased to announce its 2019 Call for Letters of Intent. Selected Letters of Intent will be featured in the Scientific Program of its Cycle II application going forward for review in July 2019 to the federal government’s Networks of Centres of Excellence (NCE) Program.

Building on previous BioCanRx investments in Cycle I, the overarching goal of the Cycle II Research Program will focus on extending immunotherapy successes in the clinic beyond initial responders. To address this challenge, while making use of technologies in the BioCanRx pipeline or by soliciting new complimentary technology, BioCanRx will invest in projects aimed at understanding patient and/or tumour type limitation(s) and proposing improved novel therapies, trials, or combination approaches to overcome the identified limitation(s)

Applications must be received by Wednesday, May 1, 2019. Full details here.